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Abstract Although beat-to-beat variability (short term variability, SV) of action 
potential duration (APD) is considered as a predictor of imminent cardiac arrhythmias, 
the underlying mechanisms are still not clear. In the present study, therefore, we aimed 
to determine the role of the major cardiac ion currents, APD, stimulation frequency and 
changes in the intracellular Ca2+ concentration ([Ca2+]i) on the magnitude of SV. Action 
potentials were recorded from isolated canine ventricular cardiomyocytes using 
conventional microelectrode techniques. SV was an exponential function of APD, when 
APD was modified by current injections. Drug-effects were characterized as relative SV 
changes by comparing the drug-induced changes in SV to those in APD according to the 
exponential function obtained with current pulses. Relative SV was increased by 
dofetilide, HMR 1556, nisoldipine and veratridine, while it was reduced by BAY K8644, 
tetrodotoxin, lidocaine, and isoproterenol. Relative SV was also increased by increasing 
the stimulation frequency and [Ca2+]i. In summary, relative SV is decreased by ion 
currents involved in the negative feedback regulation of APD (ICa, IKs and IKr), while it is 
increased by INa and Ito. We conclude that drug-induced effects on SV should be 
evaluated in relation with the concomitant changes in APD. Since relative SV was 
decreased by ion currents playing critical role in the negative feedback regulation of 
APD, blockade of these currents, or the beta-adrenergic pathway, may carry also some 
additional proarrhythmic risk in addition to their well-known antiarrhythmic action. 
 
Keywords 
short term variability – action potential duration – ion currents – canine myocytes – 
action potential configuration. 
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Introduction 
 
Beat-to-beat variability of action potential duration (also called short term variability, 
SV) is an intrinsic property of various in vivo and in vitro mammalian cardiac 
preparations including the human heart [7, 8, 21]. In spite of the fact that SV is 
considered one of the best proarrhythmic predictors [1, 11, 22] (but see also Michael et 
al. 2007 [17]), its exact ionic mechanism is poorly understood. Involvement of many 
factors, such as stochastic gating of ion channels [14, 18], cell-to-cell coupling [27], 
action potential duration and morphology [6], stimulation frequency [12] and intracellular 
calcium handling [13] in modulation of SV have been reported, however, neither their 
relative contribution, nor the role of the specific cardiac ion currents have been identified 
in a well defined experimental model. Therefore, in absence of relevant human cellular 
electrophysiological data, canine ventricular myocytes were chosen to analyze 
experimentally the determinants of SV in the present study due to two reasons. (1) 
Canine ventricular myocytes are believed to resemble human ventricular cells regarding 
their action potential morphology and kinetics of the underlying ion currents [19, 20]; and 
(2) a large mass of in vitro and in vivo experimental data on beat-to-beat variability have 
been obtained in this species [1, 12, 13, 15, 22, 23]. 
 
Methods 
Isolation of single canine ventricular myocytes 
Adult mongrel dogs of either sex were anaesthetized with intramuscular injections of 10 
mg/kg ketamine hydrochloride (Calypsol, Richter Gedeon, Hungary) + 1 mg/kg xylazine 
hydrochloride (Sedaxylan, Eurovet Animal Health BV, The Netherlands) according to 
protocols approved by the local ethical committee (license No: 18/2012/DEMÁB) in line 
with the ethical standards laid down in the 1964 Declaration of Helsinki and its later 
amendments. The hearts were quickly removed and placed in Tyrode solution. Single 
myocytes were obtained by enzymatic dispersion using the segment perfusion technique, 
as described previously [2, 3, 9, 16]. Briefly, a wedge-shaped section of the ventricular 
wall supplied by the left anterior descending coronary artery was dissected, cannulated 
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and perfused with oxygenized Tyrode solution. After removal of blood the perfusion was 
switched to a nominally Ca2+-free Joklik solution (Minimum Essential Medium Eagle, 
Joklik Modification, Sigma) for 5 min. This was followed by 30 min perfusion with 
Joklik solution supplemented with 1 mg/ml collagenase (Type II. Worthington, Chemical 
Co.) and 0.2 % bovine serum albumin (Fraction V., Sigma) containing 50 µM Ca2+. All 
other drugs were obtained from Sigma-Aldrich Co. (St. Louis, MO, USA). After 
gradually restoring the normal external Ca2+ concentration, the cells were stored in 
Minimum Essential Medium Eagle until use. 
 
Recording of action potentials 
All electrophysiological measurements were performed at 37 °C. The rod-shaped viable 
cells showing clear striation were sedimented in a plexiglass chamber of 1 ml volume 
allowing continuous superfusion (at a rate of 2 ml/min) with modified Krebs solution 
gassed with a mixture of 95 % O2 and 5 % CO2 at pH = 7.4. The modified Krebs solution 
contained (in mM): NaCl, 128.3; NaHCO3, 21.4; KCl, 4.0; CaCl2, 1.8; MgCl2, 0.42; and 
glucose 10. Transmembrane potentials were recorded using 3 M KCl filled sharp glass 
microelectrodes having tip resistance between 20 and 40 MΩ. These electrodes were 
connected to the input of Multiclamp 700A, 700B or Axoclamp-2B amplifiers (Molecular 
Devices, Sunnyvale, CA, USA). The cells were paced through the recording electrode at 
steady cycle length of 1 s using 1-2 ms wide rectangular current pulses having amplitudes 
of twice the diastolic threshold. Since the cytosol was not dialyzed, time dependent 
changes in action potential morphology were negligible for the period of our 
experimental protocol lasting typically not longer than 25 min, as was demonstrated in 
Fig. 1e. Action potentials were digitized (at 200 kHz using Digidata 1322A, 1440A and 
1200 A/D card, purchased from Axon Instruments Inc., Foster City, CA, USA) and stored 
for later analysis. Series of 50 consecutive action potentials were analyzed to estimate SV 
according to the following formula: 
SV = Σ (│APDn+1 minus APDn│) / [nbeats * √2] 
where SV is short term variability, APDn and APDn+1 indicate the durations of the nth and 
n+1th APs, respectively, at 90% level of repolarization and nbeats denotes the number of 
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consecutive beats analyzed [12]. Changes in SV were typically presented as Poincaré 
plots where 50 consecutive APD values are plotted, each against the duration of the 
previous action potential. 
Here is to be mentioned that all action potentials analyzed in the present study were 
normally driven ones, records taken in myocytes displaying early or delayed 
afterdepolarizations were excluded from evaluation.  
 
Statistics 
Results are expressed as mean ± SEM values. Statistical significance of differences was 
evaluated using one-way ANOVA followed by Student's t-test. Differences were 
considered significant when p was less than 0.05. Each given n value represents the 
number of cells / number of animals. 
 
Results 
Transmural distribution of SV 
Since considerable differences are known to exist in the set and densities of ion currents, 
resulting in different action potential morphologies, in the various layers of the 
ventricular wall, SV was compared in myocytes dispersed from the subepicardial (EPI), 
subendocardial (ENDO) and midmyocardial (MID) regions of the left ventricle. SV was 
the greatest in the MID cells (2.93±0.07 ms) smallest in EPI cells (2.16±0.17 ms), and 
had an intermediate level in ENDO myocytes (2.53±0.16 ms) as demonstrated in Fig. 1a-
c. Although all these transmural differences in APD and SV were statistically significant 
when analyzed using ANOVA (p<0.05), they were not related to the spike-and-dome 
configuration of action potentials observed in EPI or MID cells. When the transient 
outward K+ current (Ito) was suppressed by 1 mM 4-aminopyridine in EPI cells, the 
spike-and-dome action potential morphology disappeared but SV decreased slightly (by 
0.57±0.49 ms, N.S., n=9/6) instead of increasing. This concentration of 4-aminopyridine 
failed to modify APD significantly (not shown). As shown in Fig. 1d, the observed 
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transmural distribution of SV was largely proportional to APD values. Therefore, the 
relationship between SV and APD was further studied. 
 
Relationship between SV and APD 
To study the dependence of SV on APD, outward and inward current injections were 
applied in current clamp mode. The current pulses, having amplitudes varied from -600 
to +70 pA, were injected throughout the full duration of the action potential except phase 
0 (Fig. 2a,b). These experiments, similarly to all results discussed in the followings, were 
performed in midmyocardial cells. Using current pulses of various amplitudes allowed 
the modification of APD within a reasonably wide range (from 20 to 500 ms) in a way 
not related to exclusive interaction with one or another specific ion current. The results 
obtained by analyzing 117 data points (i.e. corresponding SV and APD values, each 
representing a group of 50 consecutive action potentials), are presented in Fig. 2c-e. As 
shown in Fig. 2c the SV-APD relationship follows exponential kinetics. Similarly, an 
exponential relationship was observed when the current-induced changes in SV and APD 
were analyzed (Fig. 2d). Furthermore, when the relative change in SV (defined as ∆SV / 
∆APD) was plotted against the current-induced change in APD (∆APD), this relationship 
could also be fitted to an exponential function. From the ∆SV versus ∆APD and ∆SV / 
∆APD versus ∆APD relations one can estimate that a change in SV caused by any given 
drug or intervention is greater or less than the value predicted by the concomitant change 
in APD. The equations used for the fitting procedure together with their numerical 
solutions are presented in Table 1. The most important conclusion from these 
experiments is that any drug-induced change in SV must be evaluated in terms of relative 
SV, i.e. by comparing changes in SV to concomitant changes in APD. 
 
Effect of the pacing cycle length 
Since the duration of a cardiac action potential is strongly influenced by the frequency of 
stimulation, it was reasonable to study whether the frequency-dependent changes in SV 
are in line with the predictions of the APD changes. Both APD and SV increased with 
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lengthening of pacing cycle length (Fig. 3a-d). When each SV was plotted as a function 
of the corresponding APD value, and the exponential curve obtained from the 
experiments presented previously in Fig. 2. was superimposed, the experimental data 
gave a good fit to the curve – at least for cycle lengths longer than 0.5 s. SV values 
obtained at higher frequencies were larger than predicted by the APD-SV relationship 
indicating the possible contribution of factors other than APD at higher pacing 
frequencies (Fig. 3e). 
 
Effect of changes in [Ca2+]i on SV 
There are various manipulations suitable for modulation of [Ca2+]i experimentally - the 
majority of them involves interactions with sarcoplasmic reticular Ca2+ handling. Instead 
of these, the simplest strategy was followed in the present study - based on the 
assumption that if the cell is loaded directly with Ca2+, it must increase [Ca2+]i, and 
conversely, [Ca2+]i must be reduced by an intracellularly applied Ca2+-chelator. Exposure 
the cells to the Ca2+-ionophore A 23187 (1 µM for 25 min) significantly shortened, while 
loading the cells with the cell-permeant acetoxy-methylesther form of the Ca2+ chelator 
BAPTA (using 5 µM BAPTA-AM for 25 min) strongly lengthened APD, although SV 
was not modified significantly by these interventions (Fig. 4a-d). However, as 
demonstrated in Fig. 4e, A 23187 increased, while BAPTA-AM decreased the relative 
SV when it was expressed as a function of APD change, i.e. as a ∆SV / ∆APD ratio. 
 
Contribution of the major ion currents to modulation of beat-to-beat variability: role of 
K+ currents 
The role of the various ion currents in modulation of SV can be best studied by using 
their selective activators and inhibitors. Contribution of five K+ currents, the rapid 
delayed rectifier (IKr), the slow delayed rectifier (IKs), the transient outward current (Ito) 
and the inward rectifier (IK1) was studied using their specific blockers: dofetilide, HMR 
1556, chromanol 293B in the presence of HMR 1556, and BaCl2, respectively. The ATP-
sensitive K+ current (IK-ATP) was activated by lemakalim (Fig. 5a-e). Plotting the results 
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in the way as it was done in Fig. 2c-e revealed the specific effects of these agents on SV 
both absolutely and relatively (Fig. 5f-h). Accordingly, the IKr inhibitor dofetilide (10, 
30, 100 and 300 nM) increased both APD and SV, however, its effect on SV was 
significantly stronger than its effect on APD (relative enhancement of SV). Similar effect 
could be observed with the selective IKs blocker HMR 1556 (0.5 µM), which agent 
caused only a small, but statistically significant lengthening of APD combined with a 
pronounced increase in SV. This can be best visualized in Fig. 5h, where the ∆SV / 
∆APD values were displayed versus ∆APD. The diamond representing HMR 1556 is 
located far above the curve in the positive ∆APD range. This indicates that the SV-
increasing effect of HMR 1556 is much greater than predicted by the earlier discussed 
APD-SV relationship - in spite of the fact that IKs is considered to be a weak current in 
canine ventricular myocytes under baseline conditions [24, 26]. A relatively selective Ito-
blockade can be achieved by applying chromanol 293B in the presence of HMR 1556 
[25]. Exposure of myocytes to 100 µM chromanol 293B revealed that suppression of Ito 
decreased SV without significant alterations in APD, a result similar to previously 
obtained with 1 mM 4-aminopyridine. That is why the downward triangle, indicating 
chromanol 293B, is located also far above the curve (Fig. 5h). Increasing concentrations 
of lemakalim (0.1, 0.3, 1 and 5 µM) were used to shorten APD. Lemakalim decreased 
both SV and APD, but data points remained on the curve indicating that this current has 
little specific influence on SV. Suppression of IK1 with BaCl2 (gradually increasing BaCl2 
concentration from 0.3 to 5 µM) increased APD and SV, but in this case the SV-
increasing effect was weaker than predicted by the APD-SV relationship, suggesting that 
relative SV might be increased by IK1. However, as it is clearly seen in Fig. 5d, BaCl2 
caused strong triangulation of action potentials, defined as a difference between the 
APD90 and APD50 values. Triangulation was 47±3 ms under control conditions, which 
increased to 90±11 ms in the presence of 5 µM BaCl2 (p<0.05). Assuming that APD 
measured close to the plateau level may be more relevant to control action potential 
repolarization than APD90 itself, data points obtained with 5 µM BaCl2 should be shifted 
leftwards on the horizontal axis in Fig. 5f-h by 43 ms for the sake of better comparability. 
Considering these corrections due to triangulation, each BaCl2 data point touched the 
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exponential curve (not shown) indicating that IK1 is a current largely indifferent regarding 
the modulation of SV. 
 
Contribution of inward currents 
The role of Na+ current (INa) was examined by suppression of INa using TTX and 
lidocaine, or alternatively, by activation of the current by veratridine (Fig. 6a-c). As 
expected, veratridine (10, 30 and 100 nM) increased both APD and SV in a 
concentration-dependent manner, while both parameters were simultaneously decreased 
by tetrodotoxin (TTX, 3 µM) and lidocaine (50 µM). Importantly, the SV-decreasing 
effect of INa inhibition, as well as the enhancement of SV caused by veratridine, were 
larger than predicted by the APD-SV relationship (Fig. 6f-h), congruently with an SV 
increasing action of INa. The other inward current under investigation was the L-type Ca2+ 
current (ICa). It was blocked by 1 µM nisoldipine and enhanced by 20 nM or 200 nM of 
BAY K8644 (Fig. 6d,e). Nisoldipine increased SV (by 0.52±0.19 ms) while APD was 
strongly shortened (by 103±7 ms), both effects were statistically significant (p<0.05, 
n=19/13). BAY K8644 increased APD significantly in 20 nM as well as 200 nM 
concentrations (APD-lengthening of 38±4 and 82±8 ms were observed in 12/6 and 21/9 
myocytes, respectively, p<0.05). SV was not altered by 20 nM BAY K8644, but it was 
increased by 1.96±0.26 ms in the presence of 200 nM BAY K8644. As demonstrated in 
Fig. 6f-h, these changes in SV corresponded to a relative reduction of SV when 
compared to the concomitant lengthening of APD. In other words, SV was strongly 
diminished by ICa. 
  
Offsetting the effects of APD changes 
The best approach to separate the contribution of a specific ion current to modulating SV 
from the effect of the concomitant APD-change is to apply an electrical or 
pharmacological compensation. The former strategy was used in the experiments 
presented in Fig. 7a-f, where the APD-lengthening effects of 0.1 µM dofetilide, 5 µM 
BaCl2, 0.1 µM veratridine and 0.2 µM BAY K8644 were offset using outward current 
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pulses with constant, properly chosen amplitude. Similarly, the APD-shortening effects 
of 3 µM tetrodotoxin and 1 µM nisoldipine were compensated using inward current 
pulses (Fig. 7e,f). After full compensation for the dofetilide-induced lengthening of APD 
a significant elevation of SV persisted (Fig. 7a), while in the case of BaCl2 the 
enhancement of SV was eliminated by restoring the original value of APD. More 
specifically, SV, measured after compensation for the barium-induced lengthening of 
APD, fell below the control level of SV (Fig. 7b). However, applying the argumentation 
used in the case of Fig. 5d, based on the barium-induced triangulation of action 
potentials, APD50 was overcompensated by the applied outward current. This is in line 
with our previously discussed finding, i.e. suggesting that IK1 is really an indifferent 
current regarding its possible influence on SV. Similarly to results obtained with 
dofetilide, SV remained elevated in the presence of veratridine even if APD was fully 
compensated for (Fig. 7c) – in contrast to BAY K8644, which resulted in a subnormal 
level of SV after compensation for the APD-changes (Fig. 7d). When INa was blocked by 
tetrodotoxin, the SV values were lower than control following compensation of APD 
(Fig. 7e), while in the presence of the ICa blocker nisoldipine the drug-induced elevation 
of SV was further increased by the inward current pulse applied for offsetting the APD-
changes (Fig. 7f). 
Since one may argue that electrical compensation of APD-changes may shift the 
membrane potential to one or another direction, pharmacological compensation was also 
used in some experiments (Fig. 7g-j). In this case the APD-lengthening effects of 
dofetilide and veratridine were compensated by lemakalim (using properly chosen 
concentrations in each experiment), while the APD-shortening effects of tetrodotoxin and 
nisoldipine were compensated by BaCl2. Although these compensations resulted in full 
restoration of the initial APD90 values, SV remained elevated in the presence of dofetilide 
and veratridine, became higher than control in nisoldipine and lower than control in 
tetrodotoxin. In summary, electrical and pharmacological compensation strategies yielded 
largely identical results corroborating the specific SV-lowering effects of IKr and ICa, as 
well as the SV-increasing effects of INa. It must be emphasized, however, that the most 
dramatic effect was observed with nisoldipine, independently of the way of 
compensation, highlighting the pivotal role of ICa in controlling SV. 
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Effect of isoproterenol 
Summarizing the results above it could be concluded that two currents, namely ICa and 
IKs, were very effective in reducing the relative SV. If this is true, isoproterenol (ISO) is 
expected to decrease SV markedly, since this drug is known to increase both ICa and IKs 
simultaneously. ISO (10 nM) caused a small, although statistically significant shortening 
in APD at 1 Hz (reduction of 25±3 ms, p<0.05, n=13/5), which was accompanied with a 
robust decrease in SV (reduction of 0.89±0.09 ms, p<0.05, n=13/5), which was much 
larger than predicted by the APD-SV relationship (Fig. 8a-c). Indeed, the lowest SV 
could be observed at close to normal APD values in the presence of 10 nM ISO. Since 
ISO is known to increase [Ca2+]i, and changes in [Ca2+]i were shown to influence relative 
SV, the effects of ISO were studied also after the exposure to 5 µM BAPTA-AM for 25 
min. As seen previously, pretreatment with BAPTA-AM lengthened APD markedly 
without significantly affecting SV. In the presence of BAPTA-AM SV was decreased and 
APD was shortened by ISO similarly to results observed without BAPTA-AM (Fig. 8d-
e). The effect of ISO on relative SV was largely similar in the presence and absence of 
BAPTA-AM, indicating that the effect of ISO on SV was not related to the concomitant 
changes in [Ca2+]i, it was rather caused by the ISO-induced augmentation of ICa and IKs. 
Supporting this conclusion, ∆SV / ∆APD values were identical in the absence and 
presence of BAPTA-AM (0.043±0.007 (n=13/5) and 0.045±0.009 (n=7/4), respectively, 
N.S.). 
 The effect of 10 nM ISO was studied also at various pacing cycle lengths. In these 
experiments SV was determined by analyzing 10 consecutive action potentials only in 
order to limit the duration of the measurement. Although both the ISO-induced 
shortening of APD and reduction of SV increased with increasing the cycle length of 
stimulation (Fig. 8f-g), the relative SV - as demonstrated in Fig. 8h - progressively 
decreased at longer cycle lengths. 
 
Discussion 
 12 
The main goal of the present study was to separate SV changes related to inhibition of a 
specific ion current from those attributable to concomitant changes in APD. This 
approach allows for separation of ion currents to APD-stabilizing, therefore potentially 
antiarrhythmic currents (ones decrease relative SV) and to those which increase relative 
SV. Members of this latter group cause instability of APD, therefore they can be 
considered potentially arrhythmogenic. Using these categories based on predictions of 
arrhythmia incidence, 3 currents could be identified as APD-stabilizer: ICa, IKs and IKr. INa 
and Ito were found to increase instability of APD, while IK1 and IK-ATP appeared to be 
indifferent. These results provide an essentially new interpretation of beat-to-beat 
variability suggesting that the well-known negative feed-back regulation of APD may be 
an important factor of SV-modulation. 
 Effects of several ion channel modifiers (including dofetilide [12], HMR 1556 
[12], ATX-II [12] and isoproterenol [13] in canine, while tetrodotoxin [27] and 
intracellular EGTA [27] in guinea pig ventricular cells) on the magnitude of beat-to-beat 
variability have been extensively studied, however, the changes in SV were not correlated 
by the investigators with the concomitant APD changes. The first approach to make such 
a distinction was the recent study of Heijman et al. [6], although it was an in silico 
analysis. Present results, however, have confirmed many of their predictions: INa and IKr 
have great impact on SV, IKr is an APD-stabilizing, while INa and Ito are APD-
unstabilizing currents. IKs was estimated also as an APD-stabilizing current (having larger 
impact on SV than on APD) - in line with our observations, but only our analysis, based 
on comparison of ∆SV / ∆APD changes, was able to highlight the importance of this 
interaction in the case of IKs. The largest difference between our and their results was 
found in the role of ICa. Although ICa was considered to be APD-stabilizing by both 
studies, it was the most important modulator in our experiments, as indicated by the 
results obtained with nisoldipine and BAY K8644 - in contrast to the moderate effect on 
SV proposed by the simulation in Fig. 3 of the study of Heijman et al. [6]. 
 According to the conventional interpretation of beat-to-beat variability, it is due to 
the stochastic behavior of ion channel gating [14, 18]. Without questioning the 
contribution of this mechanism, here we propose another (probably more relevant) one to 
explain the observed changes in SV. Physiological control of APD is based on the 
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following well-known negative feed-back regulation scheme: prolongation of APD (e.g. 
due to the enhancement of an inward current) results in elevation of the plateau, which in 
turn accelerates the activation of IKr and IKs leading finally to a shortening of APD. 
Accordingly, those currents which are known to be critical members of this feed-back 
loop - namely ICa, IKr and IKs - are expected to decrease the variability of APD, and their 
inhibition may have an opposite effect. This interpretation provides some explanation for 
the following question: why ICa decreases while late INa increases APD. This is not 
evident since both currents are inwardly directed, tending to increase APD together with 
its variability. The crucial difference between ICa and late INa is that the former is active 
mainly during the initial part of the plateau [2], while the latter is dominant during the 
late plateau [10, 28]. As a consequence, ICa has a chance to shift the early plateau 
upwards allowing for faster and stronger activation of IKr and IKs, while in the case of late 
INa these changes develop later in time and in a less pronounced way. In line with this, the 
SV-increasing effect of late INa is strong because its activation overlaps the late plateau, 
where the membrane resistance is the highest [27], consequently, a relatively small 
inward shift in the net membrane current may result in a large prolongation of APD [3, 
4]. This gives also the physical basis of the exponential relationship between SV and 
APD, as was predicted by the simulations of Heijman et al. [6] and confirmed 
experimentally by the present work. 
 In addition to action potential duration, the morphology of action potential was 
also suggested to be an important determinant of SV [6]. Heijman et al. simulated square-
like action potential configuration by decreasing both ICa and Ito, while triangulation was 
achieved by strongly reducing IK1. SV was dramatically elevated when it was simulated 
for a square-like action potential, on the contrary, triangulation decreased relative SV. 
Indeed, characteristic changes in action potential morphology can be attributed to 
modifications of many cardiac ion currents, e.g. suppression of ICa by nisoldipine results 
in plateau depression and square-like morphology. Similarly, suppression of IK1 caused 
triangulation of action potentials, i.e. smaller increase of APD50 than that of APD90. Since 
the plateau level is critical in the negative feed-back regulation of APD, its duration is 
overestimated by APD90 in case of triangulation. This is why IK1 can not be considered as 
a potentially proarrhythmic current in dogs in spite of the reduction of relative SV 
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observed in BaCl2. Although modification of SV observed in these examples is likely 
mediated by a change in action potential morphology, this is not always the case. For 
example, exposure of EPI myocytes to 4-aminopyridine converted action potential 
morphology from EPI to ENDO, but SV was not increased accordingly. Furthermore, SV 
was reduced by ISO very effectively without causing triangulation. 
 Our results regarding the effects of the stimulation cycle length on SV is similar 
to those of Johnson et al. [12], both studies showing an elevation of SV with increasing 
the cycle length. It might be tempting to associate these frequency-dependent changes in 
SV with the corresponding changes in the amplitude of specific ion currents. Since ICa is 
known to increase, while IKs is to decrease with increasing the cycle length of 
stimulation, the value of this approach seems to be limited. However, we have shown 
also that at cycle lengths of 700 ms or longer the changes in SV was likely due to the 
concomitant alterations of APD, since no change in relative SV could be observed within 
this frequency range. Specific cycle length-dependent changes in SV could be observed 
only at the shortest cycle lengths, where [Ca2+]i could probably be elevated. Indeed, 
manipulation of [Ca2+]i resulted in the expected change in the relative SV, which 
increased and decreased together with the changes in [Ca2+]i. In line with this assumption, 
the ISO-induced reduction of relative SV also increased with increasing the cycle length 
of stimulation. Accordingly, the ISO-induced reduction of SV was not significant at the 
shortest cycle length of 0.3 s, while it became progressively dominant at longer cycle 
lengths (including the range between 0.5 and 1 s, corresponding to the physiological heart 
rate in humans). It can be speculated that the ISO-induced reduction of relative SV could 
partially be offset by the elevated [Ca2+]i at faster driving rates. It is worth mentioning 
that alternans was not observed even at the shortest cycle length of 300 ms - in contrast to 
the results of Johnson et al. [12]. This was likely the consequence of the bicarbonate 
content of our Krebs solution, which is known to provide an excellent intracellular 
buffering, decreasing thus the probability of alternans [5]. We have intentionally chosen 
the simplest way to manipulate [Ca2+]i, since both chelation of [Ca2+]i and increasing the 
calcium entry using a calcium ionophore are expected to yield steady changes in [Ca2+]i, 
relatively independent of the cardiac cycle. This allowed a qualitative prediction of SV 
changes associated with variation of [Ca2+]i, but is obviously not suitable for modeling 
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the consequences of dynamic [Ca2+]i changes occurring when transports between the 
sarcoplasmic reticulum and the cytosol are active. 
 In this investigation the possible contribution of one or another ion current to SV 
was studied by using specific activators and inhibitors of the ion channel in question. We 
tried to apply these agents in relatively selective concentrations (i.e. at concentrations 
resulting dominantly action on the targeted ion channel), while in some cases a series of 
concentrations have been applied. Serious problem with drug-selectivity arose only in the 
case of 4-aminopyridine, which is not selective blocker of Ito - not even at the 
concentration of 1 mM. Therefore selective suppression of Ito could be only achieved by 
using 100 µM chromanol 293B (of course in the presence of HMR 1556, since 
chromanol 293B is also known to inhibit IKs). Regarding the Ca2+ ionophore A 23187 and 
the Ca2+ chelator BAPTA-AM, the applied concentrations (1 and 5 µM, respectively) 
were chosen by convention, since the amount of calcium entry or calcium chelation 
depends primarily on the time of exposure. 
 In addition to the better understanding of the mechanism of beat-to-beat 
variability, there is one - quite annoying - practical implication of the present work. We 
have shown that IKr, IKs and ICa act to reduce short term variability. These are the currents 
being generally suppressed by class 3 and 4 antiarrhythmics, respectively. Furthermore, 
10 nM ISO was the most effective agent to diminish relative SV out of all drugs tested. 
Class 2 antiarrhythmics, which are beta-receptor blockers, are expected to suppress this 
apparently beneficial adrenergic activity. Although we do not intend to suggest that 
adrenergic activation itself would be antiarrhythmic, it must be clearly seen that it has 
antiarrhythmic properties as well. Putting together, almost all of the presently applied 
antiarrhythmic agents (including the less side-effect carrying beta-blockers) may 
potentially increase the beat-to-beat variability of action potential duration limiting this 
way their antiarrhythmic potencies. 
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Table 1.  Monoexponential fitting of the SV – APD relationship obtained by varying the 
amplitude of the injected current 
 
 
Eq.  y0  A  T  r2 
         
 
(1)  0 ms  0.56 ms 131 ms 0.98 
 
 
(2)  -2.39 ms 2.37 ms 97 ms  0.97 
 
 
(3)  0.008  0.016  129  0.82 
 
 
 
 
Eq. (1) SV = SV0 + A * e APD / T   
y0
 
= SV0 = 0 
 
Eq. (2) ∆SV = ∆SV0 + A * e ∆APD / T   
y0
 
= ∆SV0 
 
Eq. (3) ∆SV / ∆APD = (∆SV/∆APD)0 + A * e (∆SV/∆APD) / T    
y0
 
= (∆SV/∆APD)0 
 
 
Data were obtained using inward and outward current injections (having amplitudes of 
-600, -500, -400, -300, -200, -80, -40, 0, +30, +40, +50, +60 and +70 pA) during the full 
duration of the action potential except phase 0. 117 individual data points, obtained from 
9 myocytes of 8 dogs, were fitted to an exponential function described by Eq. (1), Eq. (2) 
or (Eq. 3), as pertinent. APD: action potential duration, SV: short term variability, r2: 
regression coefficient, y0 = minimum value of ordinate. 
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Figure legends 
 
Fig. 1 Transmural distribution of beat-to-beat variability (SV) in canine ventricular 
myocardium. Tissue chunks originating from subepicardial (EPI), subendocardial 
(ENDO) and midmyocardial (MID) layers were isolated separately, then SV and APD 
were determined for each cell. a: Superimposed sets containing 50 consecutive action 
potentials recorded from EPI, ENDO and MID cells, respectively. b:  Poincaré plots 
constructed using these sets of action potentials. Individual data (c) and average values 
(d) obtained from EPI (n=13/11), ENDO (n=18/14) and MID (n=94/48) myocytes. The 
stability of SV and APD as a function of time is demonstrated in midmyocardial cells 
(n=5/4) as shown in panel e. Columns and symbols show arithmetic means, bars denote 
SEM values and asterisks indicate statistically significant (p<0.05) differences between 
groups determined using ANOVA. 
 
Fig. 2 Beat-to-beat variability plotted as a function of action potential duration. a,b: 
Superimposed sets of action potentials recorded from myocytes exposed to current 
injections, and the corresponding Poincaré plots. Although data were obtained using 
inward and outward current injections, having amplitudes of -600, -500, -400, -300, -200, 
-80, -40, 0, +30, +40, +50, +60 and +70 pA, respectively, only the data obtained with -80, 
-40, 0, +30 and +50 pA are presented in the graph. c: SV was plotted against APD for 
each measurement including the full scale of current amplitudes. Using the non-injected 
data (zero current) as reference, the current-induced changes in SV (∆SV) were plotted 
against the current-induced changes in APD (∆APD) in panel d. Finally, the ∆SV / ∆APD 
ratios were plotted as a function of the corresponding ∆APD value (e). Solid curves were 
generated by fitting data to monoexponential functions in order to obtain the SV vs APD, 
∆SV vs ∆APD and ∆SV / ∆APD vs ∆APD relationships (estimated parameters in Table 
1). Results were obtained in 9 myocytes of 8 dogs by analyzing 117 individual data 
points, i.e. corresponding SV and APD values, each representing a group of 50 
consecutive action potentials. 
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Fig. 3 Effect of the cycle length (CL) of stimulation on beat-to-beat variability. a,b: 
Superimposed sets of action potentials recorded from myocytes paced at various cycle 
lengths, and the corresponding Poincaré plots. c,d: SV and APD, respectively, as plotted 
as a function of the pacing CL, varied from 0.3 to 5 s. e: SV values plotted against the 
corresponding APD at each CL. The solid curve indicates the SV – APD relationship 
predicted by the current injection experiments, shown in Fig. 2c. The experiments were 
performed in 8 myocytes obtained from 4 dogs. Symbols and bars denote means ± SEM 
values. 
 
Fig. 4 Dependence of beat-to-beat variability on the intracellular Ca2+ concentration 
([Ca2+]i). Cells were exposed to the Ca2+-ionophore (1 µM A 23187, n=17/9, a,b) or the 
cell-permeant Ca2+-chelator (5 µM BAPTA-AM, n=31/10, c,d), then the drug-induced 
changes in SV and APD were analyzed. Superimposed sets of action potentials (a,c) and 
average results (b,d) are presented. Columns and symbols are arithmetic means, bars 
indicate SEM values, asterisks denote significant differences from control. e: Drug-
induced changes in SV (∆SV) plotted against the concomitant change in APD (∆APD) 
compared to the predictions of the previously determined ∆SV-∆APD relationship (solid 
curve). 
 
Fig. 5 Contribution of outward membrane currents to modulation of beat-to-beat 
variability. Inhibition of the rapid delayed rectifier K+ current, IKr (using dofetilide: 10, 
30, 100, 300 nM; n = 7/5, 7/5, 30/12, 11/5), the slow delayed rectifier K+ current, IKs 
(using 0.5 µM HMR 1556; n = 11/5), the transient outward K+ current, Ito (using 100 µM 
chromanol 293B in the presence of HMR 1556; n=17/6), the inward rectifier K+ current, 
IK1 (using BaCl2: 0.3, 1, 3, 5 µM; n = 6/3, 18/7, 7/3, 27/13), and activation of the ATP-
sensitive K+ current, IK-ATP (using lemakalim: 0.1, 0.3, 1, 5 µM; n = 6/3, 6/3, 7/3, 6/3), 
respectively. a-e: superimposed sets of action potentials. f-h: Drug-induced changes in 
SV and APD induced by dofetilide (open circles), HMR 1556 (diamond), chromanol 
293B (downward triangle), BaCl2 (squares) and lemakalim (upward triangles). The filled 
circle indicates pooled control. Symbols and bars are means ± SEM values. Solid curves 
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indicate the SV-APD, ∆SV-∆APD and ∆SV/∆APD-∆APD relationships, obtained from 
the current injection experiments as shown in Fig. 2c-e. 
 
Fig. 6 Role of inward currents in the modulation of beat-to-beat variability. Inhibition 
and activation of the Na+ current (INa) and L-type Ca current (ICa), was performed using 
tetrodotoxin (TTX: 3 µM, n = 13/5, upward triangle), lidocaine (LID: 50 µM; n = 9/5; 
downward triangle), veratridine (VER: 10, 30, 100 nM; n = 6/5, 11/5, 19/10; open 
circles), nisoldipine (NISO: 1 µM; n = 19/13; diamond), and BAY K8644 (20 nM; n = 
12/6 and 200 nM; n = 21/9; squares), respectively. a-e: Superimposed sets of action 
potentials. f-h: Drug-induced changes in SV and APD. The filled circle represents pooled 
control, symbols and bars are means ± SEM values. Solid curves indicate the SV-APD, 
∆SV-∆APD and ∆SV/∆APD-∆APD relationships, obtained from the current injection 
experiments as shown in Fig. 2c-e. 
 
Fig. 7 Effects of ion currents on SV after offsetting their APD-modifying actions. Partial 
suppression of IKr (0.1 µM dofetilide, n=7/4, a) and IK1 (5 µM BaCl2, n=8/4, b) as well as 
the enhanced INa (0.1 µM veratridine, n=14/5, c) and ICa (0.2 µM BAY K8644, n=10/5, d) 
were compensated by outward currents (OC). Replacement of the suppressed INa (3 µM 
tetrodotoxin, n=8/4, e) and ICa (1 µM nisoldipine, n=10/5, f) were made by inward current 
pulses (IC). In these experiments drug-effects on APD were fully offset with current 
injections having finely adjusted amplitudes so as the pre-drug and post-drug APD values 
were largely equal. The effects of dofetilide (0.3 µM, n=5/4, g) and veratridine (0.1 µM, 
n=8/4, h) on APD were compensated by application of lemakalim, the activator of ATP-
sensitive K+ channels, while in the case of tetrodotoxin (3 µM, n=6/4, i) and nisoldipine 
(1 µM, n=7/4, j) properly chosen concentrations of BaCl2 were applied to offset the 
APD-changes. Columns and bars are means ± SEM, asterisks denote significant 
differences from control values. 
 
Fig. 8 Effects of isoproterenol on beat-to-beat variability. a,b: Superimposed sets of 
action potentials and Poincaré plots obtained in control and after exposure to 10 nM 
isoproterenol (ISO). Average ISO-induced changes in APD and SV obtained under 
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control conditions (n=13/5, c) and after 25 min exposure to 5 µM BAPTA-AM (n=7/4, 
d). The corresponding average ∆APD and ∆SV values are presented in panel e.  
f-g: Frequency-dependent effects of ISO on APD and SV (n=8/4). The ISO-induced SV-
changes (∆SV) were plotted as a function of the corresponding ∆APD values and 
presented in panel h, where the bold curve indicates the ∆SV-∆APD relationship 
obtained from current injection experiments. Columns, symbols and bars are means ± 
SEM, asterisks denote significant ISO-induced changes either in control or in the 
presence of BAPTA-AM. 
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Fig. 2
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Fig. 3
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Fig. 5
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